Maravai LifeSciences Holdings, Inc. (MRVI)

Import this data to Google Sheets with:

=jivedata("MRVI","financials")

Full statements spill as a table. For one cell: =jivedata("MRVI","Revenue") or =jivedata("MRVI","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Maravai LifeSciences Holdings, Inc.

MRVI • CIK 0001823239

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$288,945	$259,185	$185,743	$208,775
Cost of Revenue	$148,743	$150,876	$151,753	$135,927
Gross Profit	—	—	$33,990	$72,848
Operating Income (Loss)	$-31,648	$-235,617	$-215,266	$-117,073
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$617,736	$-261,482	$-234,974	$-136,488
Income Tax Expense (Benefit)	$756,111	$-1,860	$-4,212	$-408
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-138,375	$-259,622	$-230,762	$-136,080
Net Income (Loss) Attributable to Noncontrolling Interest	$-19,346	$-114,776	$-99,989	$-58,694
Net Income (Loss) Attributable to Parent	$-119,029	$-144,846	$-130,773	$-77,386
Weighted Average Number of Shares Outstanding, Basic	131,919,000	137,906,000	144,360,000	147,742,000
Selling, General and Administrative Expense	$151,390	$161,771	$145,118	$128,141
Research and Development Expense	$17,280	$19,221	$17,402	$15,223
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$-3,286	$-2,003	$200	$200
Restructuring Charges	$6,466	$-1,214	$17,827	$20,672
Costs and Expenses	$320,593	$494,802	$249,256	$111,167
InterestExpenseNonoperating	—	$47,700	$26,992	$23,957
Investment Income, Interest	$27,727	$27,403	$11,436	$8,213
Gain (Loss) on Extinguishment of Debt	$0	$-3,187	$0	$-3,413
Related Party Tax Expense Effect of Change in Allocation Methodology	$-668,886	$40	$0	$0
Other Nonoperating Income (Expense)	$-1,337	$-2,341	$-4,152	$-258

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization	$162,900	$164,474	$151,479	$142,414
Goodwill	$326,029	$159,878	$129,429	$129,429
Intangible Assets, Net (Excluding Goodwill)	$220,987	$194,957	$151,543	$138,375
Other Assets, Noncurrent	$77,622	$59,789	$41,875	$37,873
Assets	$1,487,450	$1,008,244	$770,577	$603,746
Long-term Debt, Excluding Current Maturities	$518,707	$290,492	$286,331	$145,980
Finance Lease, Liability, Noncurrent	$31,897	$31,106	$30,141	$29,591
Other Liabilities, Noncurrent	$59,494	$52,466	$36,477	$34,168
Liabilities	$697,566	$431,035	$397,866	$248,158
Cash and Cash Equivalents, at Carrying Value	$574,962	$322,399	$216,890	$70,091
Accounts Receivable, after Allowance for Credit Loss, Current	$54,605	$38,520	$25,498	$31,138
Inventory, Net	$51,397	$50,082	$40,495	$41,230
Prepaid Expense and Other Assets, Current	$17,830	$18,145	$13,368	$13,196
Assets, Current	$699,912	$429,146	$296,251	$155,655
Accounts Payable, Current	—	—	$2,910	$7,125
Accrued Liabilities, Current	$60,237	$36,407	$36,567	$30,169
Long-term Debt, Current Maturities	$5,440	$5,440	$5,440	$1,125
Liabilities, Current	$87,468	$56,971	$44,917	$38,419
Additional Paid in Capital	$128,503	$181,874	$199,177	$207,598
Retained Earnings (Accumulated Deficit)	$285,737	$140,891	$10,118	$-6,031
Accumulated Other Comprehensive Income (Loss), Net of Tax	—	—	$524	$459
Stockholders' Equity Attributable to Parent	$416,753	$325,292	$212,379	$204,622
Stockholders' Equity Attributable to Noncontrolling Interest	$373,131	$251,917	$160,332	$150,966
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$789,884	$577,209	$372,711	$355,588
Inventory, Raw Materials, Net of Reserves	$19,338	$16,974	$14,606	$12,882
Inventory, Work in Process, Net of Reserves	$12,680	$10,050	$7,318	$9,904
Inventory, Finished Goods, Net of Reserves	$19,379	$23,058	$18,571	$18,444
Finance Lease, Right-of-Use Asset, before Accumulated Amortization	$78,599	$78,599	$78,599	$78,599
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$32,214	$52,708	$68,081	$68,081
Depreciation	$12,898	$20,852	$23,558	$10,213
Operating Lease, Right-of-Use Asset	$59,746	$52,551	$39,260	$39,260
Other Assets, Miscellaneous, Noncurrent	$2,929	$3,156	$2,615	$2,615
Employee-related Liabilities, Current	$12,905	$17,163	$11,107	$11,107
Operating Lease, Liability, Current	$6,780	$7,481	$7,795	$7,795
Interest Payable, Current	$9,202	$4,566	$4,043	$4,043
Contract with Customer, Liability, Current	$3,360	$2,375	$1,986	$1,986
Accrued Professional Fees, Current	$2,277	$2,233	$1,733	$1,733
Finance Lease, Liability, Current	$633	$792	$966	$966
Sales and Excise Tax Payable, Current	$1,001	$779	$742	$742
Other Accrued Liabilities, Current	$3,656	$1,543	$1,893	$1,893
Operating Lease, Liability, Noncurrent	$47,510	$41,381	$34,035	$34,035
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$75,382	$70,061	$64,740	$64,740

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-138,375	$-259,622	$-230,762	$-136,080
Net Cash Provided by (Used in) Operating Activities	$126,224	$7,465	$-57,573	$-25,261
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$0	—	$-32	$53
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-57,176	$-252,563	$-105,509	$-199,326
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$574,962	$322,399	$216,890	$97,759
Depreciation	$12,898	$20,852	$23,558	$22,121
Payments to Acquire Businesses, Net of Cash Acquired	$69,622	$0	$18,990	$0
Amortization of Intangible Assets	$27,356	$27,531	$27,951	$26,662
Payments to Acquire Property, Plant, and Equipment	$65,553	$29,658	$13,149	$9,847
Operating Lease, Right-of-Use Asset, Amortization Expense	$8,527	$8,482	$8,963	$7,778
Amortization of Debt Issuance Costs	$2,929	$2,896	$1,654	$1,654
Payments for (Proceeds from) Other Investing Activities	—	—	$0	$0
Share-based Payment Arrangement, Noncash Expense	$34,588	$49,415	$30,174	$29,930
Net Cash Provided by (Used in) Investing Activities	$-122,310	$-24,316	$-31,405	$-9,847
Gain (Loss) on Extinguishment of Debt	$0	$-3,187	$0	$-3,413
Deferred Income Tax Expense (Benefit)	$754,942	$11	$-20	$-20
Asset Impairment Charges	—	—	$84,597	$41,130
Other Noncash Income (Expense)	$2,313	$-833	$-212	$544
Repayments of Long-term Debt	$5,440	$234,393	$5,440	$296,960
Payments of Debt Issuance Costs	—	$1,241	$0	$3,575
Proceeds from Derivative Instrument, Financing Activities	$6,168	$9,287	$1,375	$1,375
Payment for Contingent Consideration Liability, Financing Activities	—	—	$6,800	$6,800
Proceeds from (Payments for) Other Financing Activities	—	—	$-5,644	$-7,104
Net Cash Provided by (Used in) Financing Activities	$-61,090	$-235,712	$-16,499	$-164,271
Interest Paid, Excluding Capitalized Interest, Operating Activities	$44,256	$50,973	$24,976	$26,079
Income Taxes Paid, Net	$-2,987	$670	$-555	$-20
Capital Expenditures Incurred but Not yet Paid	$2,011	$2,616	$3,669	$2,486
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$32,862	$0	$0	$0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$3,931	$1,287	$463	$0
Increase (Decrease) in Accounts Receivable	$-84,395	$-14,359	$-12,816	$3,471
Increase (Decrease) in Inventories	$-649	$-377	$-7,999	$-3,707
Increase (Decrease) in Prepaid Expense and Other Assets	$-8,136	$-1,966	$-1,626	$-2,909
Increase (Decrease) in Other Operating Assets	—	—	$-181	$-181
Increase (Decrease) in Accounts Payable	$5,284	$723	$-7,347	$-4,059
Increase (Decrease) in Accrued Liabilities	$15,108	$-22,754	$-4,626	$-15,521
Increase (Decrease) in Other Noncurrent Liabilities	$-15,978	$-6,299	$-18,631	$-5,846

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("MRVI","financials")

Full statements spill as a table. For one cell: =jivedata("MRVI","Revenue") or =jivedata("MRVI","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.